Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Danish leader will face a challenging landscape among competitors ...

We recently published 10 Stocks Hit by Painful Plunge. Novo Nordisk A/S (NYSE:NVO) is one of the best-performing stocks on ...

Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, ...

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...

Novo Nordisk (NVO) was downgraded to Hold from Buy at HSBC following the company’s recent warning that its 2025 exit growth rate will likely settle into mid-single digits. This adjustment reflects ...

The results of the SURPASS-CVOT trial showed that dual GLP-1/GIP agonist Mounjaro (tirzepatide) was as effective as Lilly's ...

Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...

July's jobs report reveals mixed signals. Discover key sectors with growth momentum and risks in labor trends to ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Recent global health news highlights the expansion of WuXi Apptec, Nigerian nurses striking for better conditions, Biogen’s ...